within Pharmacolibrary.Drugs.ATC.C;

model C02DC01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 0.00016999999999999999,
    adminDuration  = 600,
    adminMass      = 5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.197,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.007666666666666667,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C02DC01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Minoxidil is a direct vasodilator primarily used to treat severe hypertension that is resistant to other treatments. It is also available as a topical preparation for the treatment of androgenetic alopecia (pattern hair loss). Minoxidil is approved for use in many countries both as an antihypertensive (oral) and for hair regrowth (topical).</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic profile in healthy adult subjects following oral administration.</p><h4>References</h4><ol><li><p>Gupta, AK, et al., &amp; Williams, G (2022). Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia. <i>The Journal of dermatological treatment</i> 33(7) 2946–2962. DOI:<a href=&quot;https://doi.org/10.1080/09546634.2022.2109567&quot;>10.1080/09546634.2022.2109567</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35920739/&quot;>https://pubmed.ncbi.nlm.nih.gov/35920739</a></p></li><li><p>Gupta, AK, et al., &amp; Bamimore, MA (2022). Minoxidil: a comprehensive review. <i>The Journal of dermatological treatment</i> 33(4) 1896–1906. DOI:<a href=&quot;https://doi.org/10.1080/09546634.2021.1945527&quot;>10.1080/09546634.2021.1945527</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34159872/&quot;>https://pubmed.ncbi.nlm.nih.gov/34159872</a></p></li><li><p>Gupta, AK, et al., &amp; Shemer, A (2024). Efficacy and safety of low-dose oral minoxidil in the management of androgenetic alopecia. <i>Expert opinion on pharmacotherapy</i> 25(2) 139–147. DOI:<a href=&quot;https://doi.org/10.1080/14656566.2024.2314087&quot;>10.1080/14656566.2024.2314087</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38315101/&quot;>https://pubmed.ncbi.nlm.nih.gov/38315101</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C02DC01;
